CY1111316T1 - Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης - Google Patents
Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινηςInfo
- Publication number
- CY1111316T1 CY1111316T1 CY20111100040T CY111100040T CY1111316T1 CY 1111316 T1 CY1111316 T1 CY 1111316T1 CY 20111100040 T CY20111100040 T CY 20111100040T CY 111100040 T CY111100040 T CY 111100040T CY 1111316 T1 CY1111316 T1 CY 1111316T1
- Authority
- CY
- Cyprus
- Prior art keywords
- rheumatoid arthritis
- thiazolo
- amino
- substituted
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0500767 | 2005-04-06 | ||
| EP06717078A EP1869056B1 (en) | 2005-04-06 | 2006-04-03 | Novel 5-substituted 7-amino-ý1,3¨thiazoloý4,5-d¨pyrimidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1111316T1 true CY1111316T1 (el) | 2015-08-05 |
Family
ID=37073739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20111100040T CY1111316T1 (el) | 2005-04-06 | 2011-01-13 | Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης |
Country Status (30)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006046739A1 (ja) | 2004-10-29 | 2006-05-04 | Eisai R & D Management Co., Ltd. | 炎症性疾患治療剤 |
| AR053347A1 (es) | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| TW200820973A (en) | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| EP2069365A4 (en) * | 2006-09-29 | 2011-11-02 | Astrazeneca Ab | NOVEL [1, 3] THIAZOLO [4,5-D] PYRIMIDIN-2 (3H) -AMINE 5,7-DISUBSTITUTED DERIVATIVES AND THEIR USE IN THERAPY |
| HRP20160457T1 (hr) | 2008-03-07 | 2016-05-20 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1 i cx3cr1 |
| CA2714436C (en) | 2008-03-07 | 2017-06-27 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| US8835481B2 (en) | 2008-03-07 | 2014-09-16 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1, CX3CR1 and P40 |
| US9040538B2 (en) | 2009-05-21 | 2015-05-26 | Universite Laval | Pyrimidines as novel therapeutic agents |
| JO3437B1 (ar) | 2009-10-30 | 2019-10-20 | Esai R & D Man Co Ltd | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها |
| JP6076913B2 (ja) | 2010-12-07 | 2017-02-08 | ドレクセル ユニバーシティ | 癌からの転移を阻害する方法 |
| TWI543975B (zh) | 2011-09-13 | 2016-08-01 | Eisai R&D Man Co Ltd | Pyrrolidin-3-yl acetic acid derivatives |
| US8476301B2 (en) | 2011-09-13 | 2013-07-02 | Eisai R&D Management Co., Ltd. | Pyrrolidin-3-ylacetic acid derivative |
| JP5872105B2 (ja) | 2013-03-12 | 2016-03-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピロリジン−３−イル酢酸誘導体の塩およびその結晶 |
| EP3049086A4 (en) | 2013-09-27 | 2017-02-22 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| US20180222922A1 (en) * | 2015-06-08 | 2018-08-09 | The Johns Hopkins University | Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1) |
| US11267817B2 (en) | 2017-05-02 | 2022-03-08 | Drexel University | Substituted pyrrolo[1,2-a]quinoxalin-4(5H)-ones as CX3CR1 antagonists |
| GB201807898D0 (en) * | 2018-05-15 | 2018-06-27 | Kancera Ab | New processes and products with increased chiral purity |
| GB201811169D0 (en) | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
| AU2023362450A1 (en) | 2022-10-19 | 2025-05-29 | Astrazeneca Ab | 2,4,6-trisubstituted 1,3,5-triazines as modulators of cx 3 cr1 |
| WO2025219939A1 (en) | 2024-04-17 | 2025-10-23 | Astrazeneca Ab | Salts and polymorphs of cx3cr1 modulators |
| WO2025219950A1 (en) | 2024-04-18 | 2025-10-23 | Astrazeneca Ab | Small molecule cx3cr1 modulators |
| WO2025219947A1 (en) | 2024-04-18 | 2025-10-23 | Astrazeneca Ab | Thio-substituted 1,3,5-triazine cx3cr1 modulators |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE543978A (cg-RX-API-DMAC7.html) | 1955-01-03 | |||
| US4698327A (en) | 1985-04-25 | 1987-10-06 | Eli Lilly And Company | Novel glycopeptide derivatives |
| US4639433A (en) | 1985-08-14 | 1987-01-27 | Eli Lilly And Company | Glycopeptide derivatives |
| US4643987A (en) | 1985-08-14 | 1987-02-17 | Eli Lilly And Company | Modified glycopeptides |
| ZA909847B (en) | 1989-12-13 | 1992-08-26 | Lilly Co Eli | Glycopeptide derivatives |
| US5202328A (en) | 1991-03-06 | 1993-04-13 | Merck & Co., Inc. | Substituted fused pyrimidinones |
| US5840684A (en) | 1994-01-28 | 1998-11-24 | Eli Lilly And Company | Glycopeptide antibiotic derivatives |
| PT891978E (pt) * | 1997-07-18 | 2002-07-31 | Hoffmann La Roche | Derivados de 5h-tiazolo (3,2-a) pirimidina |
| WO1999051608A1 (en) | 1998-04-03 | 1999-10-14 | Du Pont Pharmaceuticals Company | THIAZOLO[4,5-d]PYRIMIDINES AND PYRIDINES AS CORTICOTROPIN RELEASING FACTOR (CRF) ANTAGONISTS |
| DE69936052T2 (de) | 1998-05-01 | 2008-01-17 | Eli Lilly And Co., Indianapolis | N1 modifizierte glycopeptide |
| SE9802729D0 (sv) | 1998-08-13 | 1998-08-13 | Astra Pharma Prod | Novel Compounds |
| SE9903544D0 (sv) * | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359081A (en) * | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| WO2001058906A1 (en) * | 2000-02-11 | 2001-08-16 | Astrazeneca Ab | Pyrimidine compounds and their use as modulators of chemokine receptor activity |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| RU2340611C2 (ru) * | 2000-09-15 | 2008-12-10 | Вертекс Фармасьютикалз Инкорпорейтед | Производные пиразола, используемые в качестве ингибиторов протеинкиназы |
| SE0004110L (sv) | 2000-11-10 | 2002-05-11 | Forsheda Ab | Tätningsring |
| SE0101082D0 (sv) | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| GB0221829D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| EP3597262B1 (en) * | 2002-12-20 | 2023-12-27 | Xeris Pharmaceuticals, Inc. | Formulation for intracutaneous injection |
| US20070142386A1 (en) | 2003-10-07 | 2007-06-21 | Astrazeneca | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 |
| US20090239882A1 (en) * | 2004-12-17 | 2009-09-24 | Astrazeneca Ab | Thiazolopyramidine Compounds for the Modulation of Chemokine Receptor Activity |
| AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
-
2006
- 2006-03-04 UA UAA200710491A patent/UA90707C2/ru unknown
- 2006-03-27 AR ARP060101169A patent/AR055890A1/es not_active Application Discontinuation
- 2006-03-28 TW TW095110726A patent/TW200714605A/zh unknown
- 2006-03-29 SA SA06270072A patent/SA06270072B1/ar unknown
- 2006-04-03 KR KR1020077022813A patent/KR101335055B1/ko not_active Expired - Fee Related
- 2006-04-03 CA CA2604017A patent/CA2604017C/en not_active Expired - Fee Related
- 2006-04-03 SI SI200630886T patent/SI1869056T1/sl unknown
- 2006-04-03 DK DK06717078.7T patent/DK1869056T3/da active
- 2006-04-03 HR HR20110047T patent/HRP20110047T1/hr unknown
- 2006-04-03 MX MX2007012060A patent/MX2007012060A/es active IP Right Grant
- 2006-04-03 AT AT06717078T patent/ATE487727T1/de active
- 2006-04-03 ES ES06717078T patent/ES2354450T3/es active Active
- 2006-04-03 DE DE602006018124T patent/DE602006018124D1/de active Active
- 2006-04-03 PT PT06717078T patent/PT1869056E/pt unknown
- 2006-04-03 US US11/910,780 patent/US7947693B2/en active Active
- 2006-04-03 AU AU2006231836A patent/AU2006231836B2/en not_active Ceased
- 2006-04-03 PL PL06717078T patent/PL1869056T3/pl unknown
- 2006-04-03 EP EP06717078A patent/EP1869056B1/en active Active
- 2006-04-03 NZ NZ561460A patent/NZ561460A/en not_active IP Right Cessation
- 2006-04-03 WO PCT/SE2006/000399 patent/WO2006107258A1/en not_active Ceased
- 2006-04-03 JP JP2008505262A patent/JP5165553B2/ja active Active
- 2006-04-03 RS RS20110006A patent/RS51581B/sr unknown
- 2006-04-03 RU RU2007140551/04A patent/RU2419623C2/ru not_active IP Right Cessation
- 2006-04-03 CN CN2006800200726A patent/CN101193897B/zh active Active
- 2006-04-03 BR BRPI0609738-3A patent/BRPI0609738A2/pt not_active IP Right Cessation
- 2006-04-04 UY UY29454A patent/UY29454A1/es not_active Application Discontinuation
-
2007
- 2007-09-11 IL IL185912A patent/IL185912A0/en unknown
- 2007-09-25 ZA ZA200708187A patent/ZA200708187B/xx unknown
- 2007-11-05 NO NO20075603A patent/NO20075603L/no not_active Application Discontinuation
-
2010
- 2010-12-28 US US12/979,720 patent/US9440992B2/en active Active
-
2011
- 2011-01-13 CY CY20111100040T patent/CY1111316T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111316T1 (el) | Νεα παραγωγα 5-υποκατεστημενο 7-αμινο-[1,3]θειαζολο[4,5-d] πυριμιδινης | |
| CY1107856T1 (el) | Παραγωγα ιμιδαζολιου ως ανταγωνιστες υποδοχεα γλουταμινικου | |
| WO2007002293A3 (en) | Azaindazole compounds and methods of use | |
| CY1110952T1 (el) | Παραγωγα κινουκλιδινης και η χρηση αυτων ως μουσκαρινικοι ανταγωνιστες υποδοχεων μ3 | |
| CY1110247T1 (el) | Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων | |
| CY1107401T1 (el) | Παραγωγα βενζοθειαζολιου πα την θεραπευτικη αντιμετωπιση της νοσου alzheimer και της νοσου parkinson | |
| CY1111757T1 (el) | Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α | |
| CY1111032T1 (el) | Παραγωγα τετραλινης και ινδανιου και οι χρησεις αυτων | |
| SE0402735D0 (sv) | Novel compounds | |
| NO20075610L (no) | Nye 5,7-disubstituerte [1,3]tiazol[4,5-d]pyrlmldin-2(3H)-onderivater | |
| NO20071703L (no) | Kinazolinderivater | |
| EP2155203A4 (en) | Azaindazole compounds and methods of use | |
| CY1108752T1 (el) | Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα | |
| CY1111921T1 (el) | 7-[2-[4-(6-ΦΘΟΡΟ-3-ΜΕΘΥΛ-1,2-ΒΕΝΖΙΣΟΞΑΖΟΛ-5-ΥΛ)-1-ΠΙΠΕΡΑΖΙΝΥΛ]ΑΙΘΥΛ]-2-(1-ΠΡΟΠΥΝΥΛ)-7Η-ΠΥΡΑΖΟΛΟ-[4,3-e]-[1,2,4]-ΤΡΙΑΖΟΛΟ[1,5-c]ΠΥΡΙΜΙΔΙΝ-5-ΑΜΙΝΗ | |
| CY1114803T1 (el) | Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης | |
| CY1111747T1 (el) | 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα | |
| MY169274A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| UY31734A (es) | Nuevos derivados 258 5, 7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona | |
| NO20080418L (no) | Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme | |
| WO2008039139A8 (en) | Novel 5,7-disubstituted [1, 3] thiazolo [4, 5] pyrimidin-2 (3h)-amine derivatives and their use in therapy | |
| MX2009003005A (es) | Nuevos derivados 5,7-disustituidos de [1,3] tiazolo [4,5-d]pirimidin-2(3h)-ona y su uso en terapia. | |
| ATE482955T1 (de) | Azabicyclooctan-3-onderivate und deren verwendung | |
| NO20080671L (no) | Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister | |
| TW200700067A (en) | Substituted aryl 1,4-pyrazine derivatives | |
| DE602006017849D1 (de) | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc-chemokinrezeptors |